Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
Ronald Goldenberg, Alice Cheng, Tess Fitzpatrick, et al.
Stroke (2022) Vol. 53, Iss. 5, pp. 1813-1822
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

2024 ESC Guidelines for the management of peripheral arterial and aortic diseases
Lucia Mazzolai, Gisela Teixidó‐Turà, Stefano Lanzi, et al.
European Heart Journal (2024)
Open Access | Times Cited: 122
Diabetes and Stroke: What Are the Connections?
Ofri Mosenzon, Alice Cheng, Alejandro A. Rabinstein, et al.
Journal of Stroke (2023) Vol. 25, Iss. 1, pp. 26-38
Open Access | Times Cited: 105
Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications
Dongrong Yang, Meng‐Yan Wang, Chenglin Zhang, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 32
Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis
Maria‐Ioanna Stefanou, Aikaterini Theodorou, Konark Malhotra, et al.
European Stroke Journal (2024) Vol. 9, Iss. 3, pp. 530-539
Open Access | Times Cited: 17
GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage
Brady Park, Ehab Bakbak, Hwee Teoh, et al.
AJP Heart and Circulatory Physiology (2024) Vol. 326, Iss. 5, pp. H1159-H1176
Closed Access | Times Cited: 15
2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults
G.B. John Mancini, Eileen O’Meara, Shelley Zieroth, et al.
Canadian Journal of Cardiology (2022) Vol. 38, Iss. 8, pp. 1153-1167
Open Access | Times Cited: 42
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 12
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities
Simona Sacco, Matteo Foschi, Raffaele Ornello, et al.
Diabetologia (2024) Vol. 67, Iss. 7, pp. 1192-1205
Open Access | Times Cited: 8
SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
Bartosz Rolek, Mateusz Haber, Magdalena Gajewska, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 8, pp. 322-322
Open Access | Times Cited: 20
Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors
Brian G. Wiener, Marlis Gnirke, Susi Vassallo, et al.
Clinical Toxicology (2024) Vol. 62, Iss. 2, pp. 131-133
Closed Access | Times Cited: 7
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms
Bruno Vergès, Victor Aboyans, Denis Angoulvant, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 26
Glucagon-Like Peptide 1: An Introduction and Possible Implications for Neuropsychiatry
Wilfredo López-Ojeda, Robin A. Hurley
Journal of Neuropsychiatry (2024) Vol. 36, Iss. 2, pp. A4-86
Closed Access | Times Cited: 5
A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy
Mengyue Yao, Yulei Hao, Tian Wang, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 12
Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
André Scheen
Diabetes & Metabolism (2023) Vol. 49, Iss. 5, pp. 101474-101474
Closed Access | Times Cited: 11
Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists
Osvaldo P. Almeida
Current Opinion in Psychiatry (2025)
Closed Access
Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation
Luca Sgarra, Vanessa Desantis, Andrea Matteucci, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 660-660
Open Access
The immunomodulatory effects of GLP-1 receptor agonists in neurogenerative diseases and ischemic stroke treatment
Haohui Sun, Yue Hao, Hao Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Xi Tan, Yuanjie Liang, Jigar Rajpura, et al.
Cardiovascular Diabetology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 10
Impact of ADA Guidelines and Medication Shortage on GLP-1 Receptor Agonists Prescribing Trends in the UK: A Time-Series Analysis with Country-Specific Insights
Ahmed R. N. Ibrahim, Khalid Orayj
Journal of Clinical Medicine (2024) Vol. 13, Iss. 20, pp. 6256-6256
Open Access | Times Cited: 3
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention
Dimitrios Sagris, George Ntaios, Haralampos Milionis
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 95, Iss. 3, pp. 264-272
Open Access | Times Cited: 7
Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis
Andrew J. Krentz, Stephan Jacob, Christian Heiß, et al.
Atherosclerosis (2024) Vol. 396, pp. 118528-118528
Closed Access | Times Cited: 2
Glucagonlike peptide‐1 receptor agonists versus dipeptidyl peptidase‐4 inhibitors in ischemic strokes with diabetes 2
Sidsel Hastrup, Jakob Nebeling Hedegaard, Grethe Andersen, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Additional Evidence for the Relationship Between Type 2 Diabetes and Stroke Through Observational and Genetic Analyses
Wenqiang Zhang, Li Zhang, Jingwei Zhu, et al.
Diabetes (2023) Vol. 72, Iss. 11, pp. 1671-1681
Open Access | Times Cited: 5
Cerebral microvascular matrix metalloproteinase-3 (MMP3) contributes to vascular injury after stroke in female diabetic rats
Yasir Abdul, Sarah Jamil, Weiguo Li, et al.
Neurochemistry International (2022) Vol. 162, pp. 105462-105462
Open Access | Times Cited: 8
Hyperglycemia and Venous Thromboembolism
Neha Panchagnula, William P. Brasher
Diagnostics (2024) Vol. 14, Iss. 17, pp. 1994-1994
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top